Patients with metastatic non small cell lung cancer without molecular alterations or PD L1 expression in Germany. Treatment and first outcome from the prospective German …

Purpose: Guidelines for stage IV NSCLC recommend stratified treatment by biomarker test results. We used CRISP to evaluate treatment and outcome of patients (pts) in whom neither targetable molecular alterations nor any PD-L1 expression were detected.Methods: Currently 163 sites in Germany have recruited> 4255 pts at start of 1st-line who will be followed until death or end of project. Data from 2204 pts recruited by 133 sites from 12/2015 to 06/2018 was analyzed. These pts started treatment prior approval of immune checkpoint inhibitors (ICI) for this group of pts. Progression-free survival (PFS) was determined in pts≥ 1 year under observation (recruited until 06/2017 (n= 906), outcome sample (ous)).Results: 6% of pts with non-squamous (nsq) and 35% with squamous (sq) tumors received no type of biomarker testing prior to start of 1st-line, and in 49% and 36% no targetable alterations or any PD-L1 …